Lyell Immunopharma (LYEL)
NASDAQ:LYEL
Want to see LYEL full AI Analyst Report?
LYEL Stock Chart & Stats
$24.01
-$0.01(-1.66%)
At close: 4:00 PM EST
$24.01
-$0.01(-1.66%)
Day’s Range― - ―
52-Week Range$7.65 - $45.00
Previous CloseN/A
Volume124.06K
Average Volume (3M)100.00K
Market Cap
$480.65M
Enterprise Value$462.31M
Total Cash (Recent Filing)$247.22M
Total Debt (Recent Filing)$41.92M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
May 12, 2026EPS Estimate
-2.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.85
Shares Outstanding23,332,523
10 Day Avg. Volume100,376
30 Day Avg. Volume99,996
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.12
Price to Sales (P/S)14614.51
P/FCF Ratio-3.49
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue12.84K
Enterprise Value/Gross Profit-195.81
Enterprise Value/Ebitda-2.40
Forecast
1Y Price Target
$41.00Price Target Upside70.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-9.71
Revenue Forecast (FY)$15.33K
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationAnalyst notes the dual-target CAR T-cell therapy ronde-cel has demonstrated improved effectiveness and a cleaner safety profile versus standard CAR T-cell therapies in trials, supporting potential preference in second-line diffuse large B-cell lymphoma.
Financial And Operational ReadinessAnalyst highlights the company’s strong cash position, absence of debt, and available manufacturing capacity to support upcoming pivotal readouts and initial commercialization plans, reducing near-term funding risk.
New Therapeutic OpportunityLYL273 shows encouraging activity with manageable safety in metastatic colorectal cancer early studies, creating a distinct commercial opportunity beyond the lymphoma franchise.
Bears Say
Efficacy RiskKey risk includes the possibility that a lead asset may show reduced efficacy in later trials, which could erode expected clinical advantages and limit market adoption.
Insufficient Public DetailExcerpt lacks clinical, financial, and strategic details needed to fully evaluate the analyst's recommendation, which could leave investors with limited visibility into key drivers of value.
Safety And Adoption RiskUnexpected safety issues with a lead therapy could alter its risk-benefit profile and restrict use in community settings, slowing commercial uptake despite promising efficacy signals.
Lyell Immunopharma News
LYEL FAQ
What was Lyell Immunopharma’s price range in the past 12 months?
Lyell Immunopharma lowest stock price was $7.65 and its highest was $45.00 in the past 12 months.
What is Lyell Immunopharma’s market cap?
Lyell Immunopharma’s market cap is $480.65M.
When is Lyell Immunopharma’s upcoming earnings report date?
Lyell Immunopharma’s upcoming earnings report date is May 12, 2026 which is in 12 days.
How were Lyell Immunopharma’s earnings last quarter?
Lyell Immunopharma released its earnings results on Mar 12, 2026. The company reported -$6.85 earnings per share for the quarter, missing the consensus estimate of -$2.232 by -$4.618.
Is Lyell Immunopharma overvalued?
According to Wall Street analysts Lyell Immunopharma’s price is currently Undervalued.
Does Lyell Immunopharma pay dividends?
Lyell Immunopharma does not currently pay dividends.
What is Lyell Immunopharma’s EPS estimate?
Lyell Immunopharma’s EPS estimate is -2.28.
How many shares outstanding does Lyell Immunopharma have?
Lyell Immunopharma has 23,332,523 shares outstanding.
What happened to Lyell Immunopharma’s price movement after its last earnings report?
Lyell Immunopharma reported an EPS of -$6.85 in its last earnings report, missing expectations of -$2.232. Following the earnings report the stock price went down -14.228%.
Which hedge fund is a major shareholder of Lyell Immunopharma?
Currently, no hedge funds are holding shares in LYEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lyell Immunopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.00 (70.76% Upside)
$41.00 (70.76% Upside)
Blogger Sentiment
Bullish
LYEL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 98.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $24.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.2%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
176.86%
12-Months-Change
Fundamentals
Return on Equity
-90.52%
Trailing 12-Months
Asset Growth
-30.72%
Trailing 12-Months
Company Description
Lyell Immunopharma
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
LYEL Stock 12 Month Forecast
Average Price Target
$41.00
▲(70.76% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
Mereo Biopharma Group Plc
―
Replimune Group
―
―
Ownership Overview
47.36% Insiders
7.20% Mutual Funds
0.05% Other Institutional Investors
41.42% Public Companies and
Individual Investors